博乐欣治疗抑郁症的临床价值及安全性观察

Bo LeXin Treating Depression Clinical Value and Safety Observation

目的:研究分析博乐欣应用于抑郁症的临床治疗价值及安全性。方法选择2013年4月~2014年4月期间在我院接受治疗的82例抑郁症患者,按照入院顺序的单双码将其分成对照组与观察组,对照组41例患者应用氯丙咪嗪治疗;观察组41例患者应用博乐欣治疗。结果观察组41例患者的总有效率87.80%(36/41)与对照组的85.37%(35/41)相比,差异P>0.05不具统计学意义。两组患者的HAMD评分与治疗前相比均有所降低,但是观察组患者降低程度更为显著,差异P<0.05有统计学意义。并且观察组患者的起效时间(5.69±3.56)d明显小于对照组的(12.75±5.64)d,差异P<0.05有统计学意义。结论博乐欣应用于抑郁症的治疗具有同氯丙咪嗪相当的疗效,但是能够显著减小HAMD评分,有效控制抑郁症状。

Objective to analyze the clinical therapeutic value and safety of venlafaxine in depression study.Methods 82 patients with depression were selected in 2013 April-2014 year during April in our hospital,according to the order of admission of single and double code wil be divided into the control group and the observation group,the control group of 41 cases treated with clomipramine in treatment;observation patients with venlafaxine in the treatment group of 41 cases.Results the observation group of 41 patients with the total ef ective rate was 87.80%(36/41)and 85.37%in the control group(35/41)compared with P&gt 0.05,dif erence was not statistical y significant.Compared with the decrease of HAMD score and two groups of patients before treatment,but the patients in observation group decreased more significantly,the dif erence was statistical y significant P<0.05.The onset time and observation group were(5.69±3.56)d was significantly less than the control group(12.75±5.64)d,P&lt 0.05 has significant dif erence.Conclusion the treatment of venlafaxine in depression has the same ef icacy of clomipramine considerable,but can decrease the HAMD score,the ef ective control of depressive symptoms.